A double-blind, randomized, multiple-dose and single-dose crossover, 2-part study to evaluate safety, tolerability and pharmacokinetics of injectable WCK 4282 (FEP-TAZ) in healthy male and female subjects.

Trial Profile

A double-blind, randomized, multiple-dose and single-dose crossover, 2-part study to evaluate safety, tolerability and pharmacokinetics of injectable WCK 4282 (FEP-TAZ) in healthy male and female subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs Cefepime/tazobactam (Primary)
  • Indications Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 May 2017 New trial record
    • 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top